Patents by Inventor Mengzhuang Cai

Mengzhuang Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 10981942
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 20, 2021
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20200239510
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: November 25, 2019
    Publication date: July 30, 2020
    Inventors: Mengzhuang CAI, Qian LIU, Ge XU, Binhua LV, Brian SEED, Jacques ROBERGE
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 10533032
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 14, 2020
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20180118773
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 3, 2018
    Inventors: Mengzhuang CAI, Qian LIU, Ge XU, Binhua LV, Brian SEED, Jacques ROBERGE
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 9834573
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Theracos Sub, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20150266915
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: February 20, 2015
    Publication date: September 24, 2015
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 8987323
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 24, 2015
    Assignee: Theracos, Inc.
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20120238510
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: June 13, 2011
    Publication date: September 20, 2012
    Applicant: Theracos, Inc.
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge